| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Gilead Sciences is experiencing significant advancements in Product/Service Development, particularly through the successful launch of Yeztugo, which strengthens its HIV franchise. The approval of innovative treatments like lenacapavir and the expansion of existing products like TRODELVY and the launch of LIVDELZI represent robust growth opportunities for the company. Overall, these developments enhance Gilead's position in the competitive pharmaceutical market. Continuous focus on innovative drug development is critical for capitalizing on current trends and patient needs. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for GILD since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.5, and the negative at -0.2 on 2025-09-29. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.2) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| GILD | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-29 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-09-28 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-09-27 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-09-26 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-09-25 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-09-24 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| 2025-09-23 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-09-22 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| 2025-09-21 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| 2025-09-20 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-09-29 17:11:53 Gilead's quarterly earnings reports show a mixed performance, with strong revenue from its HIV division but challenges in other areas impacting overall outlook. |
| 2025-09-29 17:11:53 Ongoing investigations regarding claims of fraud and illegal practices pose legal challenges for Gilead and impact investor confidence. |
| 2025-09-29 17:11:53 Strategic partnerships, such as those with PEPFAR, are essential for Gilead to broaden access to its HIV prevention therapies in low-income regions. |
| 2025-09-29 17:11:53 Gilead Sciences has shown fluctuating stock performance, responding to market conditions and investor sentiment, reflecting both gains and losses within recent trading sessions. |
| 2025-09-29 17:11:53 Gilead's progress in developing and receiving approval for innovative HIV drugs, such as the twice-yearly lenacapavir, significantly bolsters its position in the market. |